|
|
 |
Unique company & technology evaluation
Chikujee Therapeutics’ Nanobindi-NA product engine
offers a potential new delivery platforms with a
distinct competitive advantage and have identified
their key attributes, based on a number of criteria
including:
 Proprietary
delivery technology
Applications
of the delivery technology within the
biopharmaceutical industry
Management/technical
expertise of the delivery specialist
Competitive
edge within the delivery technology sector
Products
in development/approved utilizing the delivery
technology
Multi-point evaluation and scoring assessment
NanoBindi-NA based drug delivery product engine
offers competitive advantage based on a number of
parameters, including:
The
technology
NanoBindi-NA delivery platform uses a Multi-stage
core-shell architecture as the targeted delivery
vehicle (TSDV) for therapeutic nucleic acids. The
unique BOSH based polymeric shell protects the
nucleic acid from degradation within the body. The
targeting ligand (receptor based) ensures active
targeting of the TSDV to the desired cell. Once
inside the cancer cell, the nucleic acid based
therapeutic drug is released, where it is most
efficacious.
The
application of the technology within a number of
therapy areas
The multi-stage shell structure allows choice in
terms of route of delivery (oral, parenteral,
transdermal, implantable), delivery of
Antisense, Ribonucleic acid inhibition (RNAi) , Gene
therapy , Nucleoside analogs , Ribozymes, and
Aptamers based drugs.
The
current status of the technology in clinical
development
Chikujee is in the preliminary stages of development
for conducting pre-clinical studies on number of
drug candidates for testing.
Competition
within the technology arena
The management team is confident that, based on our
technology platform compared to alternative drug
delivery systems to technologies under evaluation,
we have measurable competitive advantage over
competitors
The drug delivery specialist’s expertise
We intend to strategically align with number of
nucleic acid based therapeutics companies in
development, strategic alliances, financial
position, marketing presence to gain market
leadership.
The product portfolio
Drug delivery systems under evaluation, products in
development, Commercialisation/ developmental
partnerships include candidates from following
categories
-
Antisense
-
Ribonucleic acid inhibition (RNAi)
-
Gene therapy
-
Nucleoside analogs
-
Ribozymes, and
-
Aptamers
|
|
